Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bucelipase alfa

Drug Profile

Bucelipase alfa

Alternative Names: Bile salt stimulated lipase; BSSL; Exinalda; Kiobrina; recombinant human BSSL; rhBSSL

Latest Information Update: 19 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Swedish Orphan Biovitrum
  • Class
  • Mechanism of Action Lipase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malabsorption syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malabsorption syndromes

Most Recent Events

  • 02 Nov 2014 Swedish Orphan Biovitrum terminates phase III trial in Malabsorption disorders (In neonates) in Belgium, Czech Republic, Denmark, France, Germany, Hungary, Italy, Poland, Russia, Spain, Sweden and the United Kingdom (NCT01413581)
  • 27 Mar 2014 Top line adverse events and efficacy data from the phase III LAIF trial in Malabsorption disorders (in preterm neonates) released by Swedish Orphan Biovitrum
  • 05 Aug 2013 Swedish Orphan Biovitrum completes enrolment in the LAIF phase III trial for Malabsorption disorders in preterm neonates in Belgium, Czech Republic, Denmark, France, Germany, Hungary, Italy, Poland, Russia, Spain, Sweden and the United Kingdom (NCT01413581 / EudraCT2010-023909-35)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top